Valuation: Lotus Pharmaceuticals, Inc.

Market Cap 97.36L 85.08L 78.65L 72.66L 1.37Cr 94Cr 1.39Cr 9.38Cr 3.68Cr 46Cr 3.66Cr 3.58Cr 157.67Cr P/E 2009
3.88x
P/E 2010 4.84x
Enterprise Value 1.44Cr 1.26Cr 1.16Cr 1.07Cr 2.02Cr 138.15Cr 2.06Cr 14Cr 5.44Cr 68Cr 5.4Cr 5.28Cr 232.93Cr EV / Sales 2009
1.02x
EV / Sales 2010 0.95x
Free-Float
99%
Yield 2009 *
-
Yield 2010 -
Manager TitleAgeSince
Chief Executive Officer - -
Director TitleAgeSince
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+41.51%-18.92% - - 47.6L
+0.46%+3.35%+12.97%+81.10% 4.85TCr
-0.36%-1.79%+66.39%+111.26% 3.57TCr
-0.01%+0.43%-3.55%+39.25% 1.21TCr
+2.06%+0.78%+19.56%+91.84% 1.18TCr
+1.13%+0.38%+32.83%+126.50% 918.79Cr
-1.81%-4.04%+43.76%-5.22% 705.8Cr
-0.42%-0.25%+18.61%+37.23% 701Cr
-0.33%+3.31%+3.20%+227.08% 677.23Cr
+3.56%-6.15%-20.01%+13.39% 597.99Cr
Average +4.58%-0.56%+19.31%+80.27% 1.6TCr
Weighted average by Cap. +0.33%-0.63%+26.57%+86.52%

Financials

2009 2010
Net sales 5.78Cr 5.05Cr 4.67Cr 4.32Cr 8.13Cr 555.43Cr 8.27Cr 56Cr 22Cr 271.97Cr 22Cr 21Cr 936.48Cr 7.27Cr 6.35Cr 5.87Cr 5.43Cr 10Cr 698.28Cr 10Cr 70Cr 27Cr 341.92Cr 27Cr 27Cr 1.18TCr
Net income 1.64Cr 1.44Cr 1.33Cr 1.23Cr 2.31Cr 157.84Cr 2.35Cr 16Cr 6.21Cr 77Cr 6.17Cr 6.04Cr 266.12Cr 1.44Cr 1.26Cr 1.17Cr 1.08Cr 2.03Cr 138.56Cr 2.06Cr 14Cr 5.45Cr 68Cr 5.42Cr 5.3Cr 233.61Cr
Net Debt 5.29 4.63 4.28 3.95 7.44 508.49 7.58 51 20.01 248.99 19.88 19.45 857.35 4.65 4.06 3.75 3.47 6.53 446.34 6.65 44.77 17.56 218.56 17.45 17.07 752.54
Logo Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
-